Search

Your search keyword '"Tunon de Lara C"' showing total 213 results
Start Over Author "Tunon de Lara C"
213 results on '"Tunon de Lara C"'

1. Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study

Author

Houvenaeghel, G., Cohen, M., Classe, J.M., Reyal, F., Mazouni, C., Chopin, N., Martinez, A., Daraï, E., Coutant, C., Colombo, P.E., Gimbergues, P., Chauvet, M.P., Azuar, A.S., Rouzier, R., Tunon de Lara, C., Muracciole, X., Agostini, A., Bannier, M., Charaffe Jauffret, E., De Nonneville, A., and Goncalves, A.

Published
2021
Full Text
View/download PDF

20. Place du ganglion sentinelle dans les carcinomes canalaires in situ étendus traités par mastectomie. Résultats de Protocole CINNAMOME

Author

Tunon de Lara, C., primary, Macgrogan, G., additional, Giard, S., additional, Chauvet, M.-P., additional, Baranzelli, M.-C., additional, Baron, M., additional, Forestier-Lebreton, F., additional, Ladonne, J.-M., additional, Goergescu, D., additional, Dessogne, P., additional, Piquenot, J., additional, Le Bouedec, G., additional, Penault-Llorca, F., additional, Garbay, J.-R., additional, Mathieu, M.-C., additional, Blanchot, J., additional, Tas, P., additional, Aubard, Y., additional, Mollard, J., additional, Fermeau, V., additional, Martel, P., additional, Garrido, I., additional, Ferron, G., additional, Arash, R. Tabrizi, additional, Mery, E., additional, Martin-Françoise, S., additional, Delozier, T., additional, Michy, T., additional, Sagan, C., additional, Fondrinier, E., additional, Bracova, E., additional, Houvenaeghel, G., additional, Butarelli, M., additional, Lambaudie, E., additional, Jacquemier, J., additional, Loustalot, C., additional, Arnould, L., additional, Raout, I., additional, Ettore, F., additional, and Blanc-Fournier, C., additional

Published
2013
Full Text
View/download PDF

26. Ganglion axillaire sentinelle et cancer du sein de plus de 2 cm : PHRC GAS2plus

Author

Mignotte, H., primary, Faure, C., additional, Dussard, S., additional, Classe, J. -M., additional, Chauvet, M. -P., additional, Guillemin, F., additional, Belichard, C., additional, Martel, P., additional, Michaux, J. -P., additional, Loustalot, C., additional, Rouanet, P., additional, Leveque, J., additional, Lormier, G., additional, Tunon de Lara, C., additional, Barletta, H., additional, Golfier, F., additional, Forestier Lebreton, F., additional, Degroote, D., additional, Loez, P., additional, Bigote, A., additional, and Parmentier, D., additional

Published
2012
Full Text
View/download PDF

28. Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients ‘on behalf of the Group of Surgeons from the French Unicancer Federation’

Author

Classe, J. M., Baffert, S., Sigal-Zafrani, B., Fall, M., Rousseau, C., Alran, S., Rouanet, P., Belichard, C., Mignotte, H., Ferron, G., Marchal, F., Giard, S., Tunon de Lara, C., Le Bouedec, G., Cuisenier, J., Werner, R., Raoust, I., Rodier, J.-F., Laki, F., Colombo, P.-E., Lasry, S., Faure, C., Charitansky, H., Olivier, J.-B., Chauvet, M.-P., Bussières, E., Gimbergues, P., Flipo, B., Houvenaeghel, G., Dravet, F., and Livartowski, A.

Published
2012
Full Text
View/download PDF

35. Abstract P5-09-07: Risk reducing strategy in germline BRCA mutated patients with locally advanced breast cancer. Establishing mastectomy as a preventing procedure of local recurrence

Author

Tunon de Lara, C, primary, Leroux, J, additional, Bonnet, F, additional, Debled, M, additional, Barrouk-Simonet, E, additional, Quenel-Tueux, N, additional, Lagarde, P, additional, Chassaigne, F, additional, Esnaud, T, additional, Fournier, M, additional, Bubien, V, additional, Breton-Callu, C, additional, Charitansky, H, additional, Petit, A, additional, Mathoulin-Pelissier, S, additional, Macgrogan, G, additional, Longy, M, additional, and Sevenet, N, additional

Published
2019
Full Text
View/download PDF

36. Abstract P2-08-08: Isolated ipsilateral local recurrence of breast cancer: Predictive factors and prognostic impact

Author

Houvenaeghel, G, primary, de Nonneville, A, additional, Cohen, M, additional, Classe, J-M, additional, Reyal, F, additional, Mazouni, C, additional, Chopin, N, additional, Martinez, A, additional, Daraï, E, additional, Coutant, C, additional, Colombo, P-E, additional, Gimbergues, P, additional, Chauvet, M-P, additional, Azuar, A-S, additional, Rouzier, R, additional, Tunon de Lara, C, additional, Murraciole, X, additional, Agostini, A, additional, Gonçalves, A, additional, and Lambaudie, E, additional

Published
2019
Full Text
View/download PDF

37. Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast

Author

De Nonneville, A., primary, Jauffret, C., additional, Gonçalves, A., additional, Classe, J.-M., additional, Cohen, M., additional, Reyal, F., additional, Mazouni, C., additional, Chauvet, M.-P., additional, Chopin, N., additional, Colombo, P.-E., additional, Jouve, E., additional, Darai, E., additional, Rouzier, R., additional, Coutant, C., additional, Gimbergues, P., additional, Azuar, A.-S., additional, Tunon de Lara, C., additional, Lambaudie, E., additional, and Houvenaeghel, G., additional

Published
2018
Full Text
View/download PDF

38. 5-years RFS and prognostic factors study in HR-positive HER2-negative breast cancer patients treated with neoadjuvant endocrine therapy : Pooled analysis of two phase II trials

Author

Pulido, M., primary, Lerebours, F., additional, Quenel-Tueux, N., additional, Fourme, E., additional, Debled, M., additional, Becette, V., additional, Bonnefoi, H., additional, Rivera, S., additional, Mac Grogan, G., additional, Mouret-Reynier, M.-A., additional, Tunon de Lara, C., additional, Pierga, J.-Y., additional, Breton-Callu, C., additional, Venat-Bouvet, L., additional, Mathoulin-Pelissier, S., additional, Kerbrat, A., additional, Dalenc, F., additional, Sigal, B., additional, Bachelot, T., additional, and Lemonnier, J., additional

Published
2018
Full Text
View/download PDF

39. Abstract P3-01-02: Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: Axillary dissection versus no axillary dissection in patients with involved sentinel node

Author

Houvenaeghel, G, primary, Cohen, M, additional, Raro, P, additional, De Troyer, J, additional, Tunon De Lara, C, additional, Guimbergues, P, additional, Gauthier, T, additional, Faure, C, additional, Vaini-Cowen, V, additional, Lantheaume, S, additional, Regis, C, additional, Darai, E, additional, Ceccato, V, additional, D'Halluin, G, additional, Del Piano, F, additional, Villet, R, additional, Jouve, E, additional, Beedassy, B, additional, Theret, P, additional, Gabelle, P, additional, Zinzindohoue, C, additional, Opinel, P, additional, Marsollier-Ferrer, C, additional, Dhainaut-Speyer, C, additional, Colombo, P-E, additional, Di Beo, V, additional, Lambaudie, E, additional, Tallet, A, additional, and Boher, J-M, additional

Published
2018
Full Text
View/download PDF

40. Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials

Author

Pistilli, B, primary, Filleron, T, additional, Mazouni, C, additional, Zingarello, A, additional, Lacroix-Triki, M, additional, Rivera, S, additional, Coudert, B, additional, Serin, D, additional, Canon, J-L, additional, Campone, M, additional, Bachelot, T, additional, Goncalves, A, additional, Levy, C, additional, Cottu, P, additional, Petit, T, additional, Eymard, J-C, additional, Tunon De Lara, C, additional, Roché, H, additional, Roca, L, additional, Lemonnier, J, additional, and Delaloge, S, additional

Published
2018
Full Text
View/download PDF

41. Abstract P5-16-23: Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy

Author

Tunon de Lara, C, primary, Bonnet, F, additional, Debled, M, additional, Lafon, D, additional, Breton-Callu, C, additional, Rarouk-Simonet, E, additional, Fournier, M, additional, Petit, A, additional, Bubien, V, additional, Quenel-Tueux, N, additional, Lagarde, P, additional, Longy, M, additional, Macgrogan, G, additional, and Sevenet, N, additional

Published
2017
Full Text
View/download PDF

42. Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally-advanced hormone-receptor-positive breast cancer

Author

Quenel-Tueux, N, Debled, M, Rudewicz, J, MacGrogan, G, Pulido, M, Mauriac, L, Dalenc, F, Bachelot, T, Lortal, B, Breton-Callu, C, Madranges, N, Tunon de Lara, C, Fournier, M, Bonnefoi, H, Soueidan, H, Nikolski, M, Gros, A, Daly, C, Wood, H, Rabbitts, P, and Iggo, R

Abstract

Background: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally-advanced hormone- receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment. Methods: 120 post-menopausal patients were randomised to receive 1 mg anastrozole (61 patients) or 500 mg fulvestrant (59 patients) for 6 months. Genomic DNA copy number profiles were generated for a subgroup of 20 patients before and after treatment. Results: 108 patients were evaluable for efficacy and 118 for toxicity. The objective response rate determined by clinical palpation was 58.9% (95% CI 45.0-71.9) in the anastrozole arm and 53.8% (95% CI 39.5-67.8) in the fulvestrant arm. The breast- conserving surgery rate was 58.9% (95% CI 45.0-71.9) in the anastrozole arm and 50.0% (95% CI 35.8-64.2) in the fulvestrant arm. Pathological responses >50% occurred in 24 patients (42.9%) in the anastrozole arm and 13 (25.0%) in the fulvestrant arm. The Ki-67 score fell after treatment but there was no significant difference between the reduction in the two arms (anastrozole 16.7% [95%CI 13.3-21.0] before, 3.2% [95%CI 1.9-5.5] after, n=43; fulvestrant 17.1% [95%CI 13.1-22.5] before, 3.2% [95%CI 1.8-5.7] after, n=38) or between the reduction in Ki-67 in clinical responders and non- responders. Genomic analysis appeared to show a reduction of clonal diversity following treatment with selection of some clones with simpler copy number profiles. Conclusion: Both anastrozole and fulvestrant were effective and well-tolerated, enabling breast-conserving surgery in over 50% of patients. Clonal changes consistent with clonal selection by the treatment were seen in a subgroup of patients.

Published
2015

44. Facteurs pronostiques des carcinomes lobulaires infiltrants du sein : à propos de 940 cas

Author

Jauffret, C., primary, Houvenaeghel, G., additional, Classe, J.-M., additional, Garbay, J.-R., additional, Giard, S., additional, Charitansky, H., additional, Cohen, M., additional, Bélichard, C., additional, Faure, C., additional, Darai, É., additional, Hudry, D., additional, Azuar, P., additional, Villet, R., additional, Gimbergues, P., additional, Tunon de Lara, C., additional, Martino, M., additional, Coutant, C., additional, Dravet, F., additional, Chauvet, M.-P., additional, Chéreau Ewald, E., additional, Penault-Llorca, F., additional, Goncalves, A., additional, and Lambaudie, É., additional

Published
2015
Full Text
View/download PDF

45. 100 (PB-001) - 5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials

Author

Lerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, H., Rivera, S., Mac Grogan, G., Mouret-Reynier, M.A., Tunon de Lara, C., Pierga, J.Y., Breton-Callu, C., Venat-Bouvet, L., Mathoulin-Pelissier, S., Kerbrat, P., Dalenc, F., Sigal, B., Bachelot, T., Lemonnier, J., Lerebours, and Quenel-Tueux, N.

Published
2018
Full Text
View/download PDF

47. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

Author

Kenemans, P, Bundred, Nj, Foidart, Jm, Kubista, E, von Schoultz, B, Sismondi, Piero, Vassilopoulou Sellin, R, Yip, Ch, Egberts, J, Mol Arts, M, Mulder, R, van Os, S, Beckmann, Mw, Sismondi, P, Beckmann, M, Baum, M, Gray, R, Burger, Cw, van Diest PJ, Harbeck, N, Senn, Hj, Svane, G, Prins, Mh, Davidson, B, Peters, R, Longo, Ml, Kappelle, Lj, Maclennan, Ah, Baber, R, Eden, Ja, Furnival, C, Stuckey, B, Farrell, E, Singer, Cf, Marth, C, Reitsamer, R, Sevelda, P, Salzer, H, Thiel, I, Winter, R, Putyrski, L, Beliakouski, V, Gedrevich, Z, Tjalma, W, Desreux, J, Dhont, M, Depypere, H, van den Broecke, R, L'Hermite, M, Nolens, Jp, Rozenberg, S, Simon, P, Vergote, I, Gaspard, U, Janssens, D, De Gezelle, H, Merchiers, E, Aldrighi, Jm, Badalotti, M, Bagnoli, Vr, Fernandes, Ce, Ferriani, R, Pinto Neto AM, Menke, Ch, Petti, Da, Urbanetz, A, Del Giglio, A, Cunill, E, Sepúlveda, H, Soto, L, Uribe, A, Valdivia, I, Baptista, J, Loaciga, K, Bendova, M, Buchta, K, Pecha, V, Reslova, T, Hlavackova, O, Mikulik, M, Kütner, R, Padrik, P, Puistola, U, Ylikorkala, O, Mäenpää Liukko, K, Brémond, A, Faure, C, Seffert, P, Delozier, T, Espie, M, Dupaigne, D, Hoffet, M, Laffargue, F, Tunon de Lara, C, Largillier, L, Namer, M, Dognon, L, Routiot, T, This, P, Touraine, P, Kimmig, R, Kümmel, S, Weiss, J, Engel, U, Brucker, C, de Waal JC, Mallmann, P, Rühl, I, Untch, M, Neumann, C, Kulp, A, Krause Bergmann, B, Schmidt Rhode, P, Seifert Klauss, V, Wallwiener, D, Nestle Krämling, C, Starfl inger, F, Sohn, C, Bastert, G, Thomas, A, Lichtenegger, W, Höss, C, Chatsiproios, D, Jonat, W, de Wilde, R, Dewitz, T, Kühn, T, Kiesel, L, Blümel, B, Schindler, C, Splitt, G, Leitsmann, H, Köhler, U, Langanke, D, Landthaler, R, Hindenburg, Hj, Schoenegg, W, Conrad, B, Ortmann, O, Boér, K, Boros, J, Cseh, J, Kövér, E, Landherr, L, Ruzsa, A, Erfán, J, Fábián, F, Páli, K, Biglia, Nicoletta, Genazzani, Ar, Mariani, R, Martoni, A, Scambia, G, Santoro, A, Burlizzi, S, Amunni, G, Amadori, D, Noh, Dy, Kim, Jg, Ahn, Sh, Kang, Bm, Noh, Wc, Kim, Mh, Lee, Mh, Lee, Jj, Keire, G, Baltina, D, Nik Nasri, N, Gomez, P, Sivalingam, Muniandy, S, Cardenas, J, Mainero, F, Uscanga, S, Fuentes, A, Lugo, R, Heijmans, H, The, Hs, Franke, H, van Riel, J, van der Vegt, S, Boven, E, Houben, P, Kok, A, van Weering, H, van de Walle, A, Burggraaff, Jm, Alcedo, J, Kornafel, J, Litwiniuk, M, Karnicka, H, Bablok, L, Marianowski, Basta, A, Jakimiuk, A, Curescu, S, Draganescu, Me, Eniu, Ae, Zbranca, E, Peltecu, G, Ancar, V, Smetnik, V, Kullikov, Ep, Petrossian, A, Stekolschikova, O, Popov, A, Zoziouk, N, Krikunova, Li, Semiglazov, V, Konstantinova, M, Bezhenar, Vf, Diatchouk, A, Manikhas, G, Korytova, Ly, Vinogradov, V, Sokurenko, V, Baranov, An, Arkhipovsky, Vl, Bogatova, Ik, Akhmadulina, Li, Kuts, Tn, Susloparova, Sa, Mitashok, I, Kanzalie, Al, Bryuzgin, Vv, Malygin, En, Sergeev, Ie, Pasman, Nm, Akishina, Zv, Tuev, Av, Kopp, M, Soloviev, Vi, Evtushenko, Id, Ershov, Gv, Devyatchenko, Nf, Potapov, Yn, Cheporov, Sv, Ogurtsov, Av, Chrustalev, On, Lazareva, Dg, Bryukhina, E, Matrosova, M, Yu, Sl, Wong, Pc, Masak, L, Sadovsky, O, Petrovicova, Z, Suska, P, De Pablo JL, García, E, Iglesias, J, Mattsson, L, Granberg, G, Berglund, L, Friberg, B, Chen, St, Chow, Sn, Lee, Jn, Wang, Kl, Limpaphayom, Kk, Boonjong, S, Jirapinyo, M, Sakondhavat, C, Taechakraichana, N, Techatraisak, K, Wilawan, K, Tatarchuk, T, Dudar, L, Koshukova, G, Gyryachyy, V, Hotko, Ys, Kostynskyy, Y, Paramonov, V, Pertseva, T, Shparyk, Y, Tarasova, O, Kosey, N, Solskiy, Y, Smolanka, I, Kvashenko, V, Grishyna, O, Dzyak, G, Drew, Jp, Mansel, R, Williamson, J, Kingsland, Cr, Vishwanath, L, Bliss, R, Crawford, D, Winters, Z, Browell, D, Paterson, M, Ind, T, Rostom, A, and Pitkin, J.

Subjects
recurrence, treatment, Breast Cancer, menopause, hot flushes
Published
2009

49. Abstract P1-15-01: A randomized phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally-advanced hormone-receptor-positive breast cancer: First results

Author

Quenel-Tueux, N, primary, Dalenc, F, additional, Bachelot, T, additional, Pulido, M, additional, Bonnefoi, H, additional, Mauriac, L, additional, Madranges, N, additional, Iggo, R, additional, Lortal, B, additional, Tunon de Lara, C, additional, Campo, P, additional, and Debled, M, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results